Therefore, the potential roles of MGRN1 in melanomagenesis, on one hand, and in the clinical course of the disease, on the other, remain largely unexplored, thus preventing the exploitation of this protein as a potentially useful therapeutic target and/or melanoma biomarker. This evidence concerns the gene MGRN1 and melanoma.